The DUO-E phase III trial assessed the addition of immunotherapy (durvalumab, an anti-PD-L1 immunotherapy) and targeted therapy (poly (ADP-ribose) polymerase (PARP) inhibitor olaparib) to standard chemotherapy (carboplatin/paclitaxel) in advanced or recurrent endometrial cancer. Here, CD274 is linked to endometrial cancer.